PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Author
Migden, Michael R.Rischin, Danny
Schmults, Chrysalyne D.
Guminski, Alexander
Hauschild, Axel
Lewis, Karl D.
Chung, Christine H.
Hernandez-Aya, Leonel
Lim, Annette M.
Chang, Anne Lynn S.
Rabinowits, Guilherme
Thai, Alesha A.
Dunn, Lara A.
Hughes, Brett G.M.
Khushalani, Nikhil I.
Modi, Badri
Schadendorf, Dirk
Gao, Bo
Seebach, Frank
Li, Siyu
Li, Jingjin
Mathias, Melissa
Booth, Jocelyn
Mohan, Kosalai
Stankevich, Elizabeth
Babiker, Hani M.
Brana, Irene
Gil-Martin, Marta
Homsi, Jade
Johnson, Melissa L.
Moreno, Victor
Niu, Jiaxin
Owonikoko, Taofeek K.
Papadopoulos, Kyriakos P.
Yancopoulos, George D.
Lowy, Israel
Fury, Matthew G.
Affiliation
Univ Arizona, Ctr CancIssue Date
2018-07-26
Metadata
Show full item recordPublisher
MASSACHUSETTS MEDICAL SOCCitation
N Engl J Med 2018;379:341-51. DOI: 10.1056/NEJMoa1805131Journal
NEW ENGLAND JOURNAL OF MEDICINERights
Copyright © 2018 Massachusetts Medical Society.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
BACKGROUND No systemic therapies have been approved for the treatment of advanced cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy, because the mutation burden of the tumor is high and the disease risk is strongly associated with immunosuppression. In the dose-escalation portion of the phase 1 study of cemiplimab, a deep and durable response was observed in a patient with metastatic cutaneous squamous-cell carcinoma. METHODS We report the results of the phase 1 study of cemiplimab for expansion cohorts of patients with locally advanced or metastatic cutaneous squamous-cell carcinoma, as well as the results of the pivotal phase 2 study for a cohort of patients with metastatic disease (metastatic-disease cohort). In both studies, the patients received an intravenous dose of cemiplimab (3 mg per kilogram of body weight) every 2 weeks and were assessed for a response every 8 weeks. In the phase 2 study, the primary end point was the response rate, as assessed by independent central review. RESULTS In the expansion cohorts of the phase 1 study, a response to cemiplimab was observed in 13 of 26 patients (50%; 95% confidence interval [CI], 30 to 70). In the metastatic-disease cohort of the phase 2 study, a response was observed in 28 of 59 patients (47%; 95% CI, 34 to 61). The median follow-up was 7.9 months in the metastatic-disease cohort of the phase 2 study. Among the 28 patients who had a response, the duration of response exceeded 6 months in 57%, and 82% continued to have a response and to receive cemiplimab at the time of data cutoff. Adverse events that occurred in at least 15% of the patients in the metastatic-disease cohort of the phase 2 study were diarrhea, fatigue, nausea, constipation, and rash; 7% of the patients discontinued treatment because of an adverse event. CONCLUSIONS Among patients with advanced cutaneous squamous-cell carcinoma, cemiplimab induced a response in approximately half the patients and was associated with adverse events that usually occur with immune checkpoint inhibitors.Note
6 month embargo; published online: 26 July 2018ISSN
0028-47931533-4406
PubMed ID
29863979Version
Final published versionSponsors
Regeneron Pharmaceuticals; SanofiAdditional Links
http://www.nejm.org/doi/10.1056/NEJMoa1805131ae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa1805131
Scopus Count
Collections
Related articles
- Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.
- Authors: Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, Schadendorf D, Dunn LA, Hernandez-Aya L, Chang ALS, Modi B, Hauschild A, Ulrich C, Eigentler T, Stein B, Pavlick AC, Geiger JL, Gutzmer R, Alam M, Okoye E, Mathias M, Jankovic V, Stankevich E, Booth J, Li S, Lowy I, Fury MG, Guminski A
- Issue date: 2020 Jun
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
- Authors: Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, Schadendorf D, Guminski A, Hauschild A, Wong DJ, Daniels GA, Berking C, Jankovic V, Stankevich E, Booth J, Li S, Weinreich DM, Yancopoulos GD, Lowy I, Fury MG, Rischin D
- Issue date: 2020 Feb
- Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
- Authors: Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassukas ID, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG
- Issue date: 2021 Jun
- Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
- Authors: Baggi A, Quaglino P, Rubatto M, Depenni R, Guida M, Ascierto PA, Trojaniello C, Queirolo P, Saponara M, Peris K, Spagnolo F, Bianchi L, De Galitiis F, Potenza MC, Proietti I, Marconcini R, Botticelli A, Barbieri V, Licitra L, Alfieri S, Ficorella C, Cortellini A, Fargnoli MC, Troiani T, Tondulli L, Bossi P
- Issue date: 2021 Nov
- Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.
- Authors: Rischin D, Khushalani NI, Schmults CD, Guminski A, Chang ALS, Lewis KD, Lim AM, Hernandez-Aya L, Hughes BGM, Schadendorf D, Hauschild A, Thai AA, Stankevich E, Booth J, Yoo SY, Li S, Chen Z, Okoye E, Chen CI, Mastey V, Sasane M, Lowy I, Fury MG, Migden MR
- Issue date: 2021 Aug